Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor : Exempted From Public Tender Offer Obligation In Merger With EnBiotix

10/15/2021 | 02:09am EST


ę MT Newswires 2021
All news about POLYPHOR AG
10/29Polyphor, EnBiotix Shareholders Green-Light Merger, Name Change
MT
10/29Polyphor AG Announces Executive Changes
CI
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
09/01Polyphor AG signed a merger agreement to acquire EnBiotix, Inc.
CI
08/04POLYPHOR : Fails In Late-Stage Trial For Breast Cancer Combo Treatment
MT
More news
Financials
Sales 2020 14,3 M 15,5 M 15,5 M
Net income 2020 -44,9 M -48,9 M -48,9 M
Net cash 2020 25,1 M 27,3 M 27,3 M
P/E ratio 2020 -2,01x
Yield 2020 -
Capitalization 19,6 M 21,3 M 21,3 M
EV / Sales 2019 1 845x
EV / Sales 2020 4,63x
Nbr of Employees 52
Free-Float 82,3%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 1,59 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-80.44%21
CSL LIMITED9.18%100 628
WUXI BIOLOGICS (CAYMAN) INC.4.77%58 683
SAMSUNG BIOLOGICS CO.,LTD.7.87%50 240
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%33 712